English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  To examine the impact of polymorphisms of  glucose transporter 1  ( GLUT1 ) gene on the prognosis of patients with stage III non‐small cell lung cancer (NSCLC) who received radiotherapy.    Methods  Five single nucleotide polymorphisms (SNPs) (rs4658C>G, rs1385129G>A, rs3820589A>T, rs3806401A>C and rs3806400C>T) in  GLUT1  gene were evaluated in 90 patients with pathologically confirmed stage III NSCLC. A total of 21 patients were treated with radiotherapy alone, 25 with sequential chemoradiotherapy, and 44 with concurrent chemoradiotherapy. The association of the genetic variations of five SNPs with overall survival (OS) and progression‐free survival (PFS) was analyzed.    Results  Two SNPs (rs1385129 and rs3806401) were significant risk factors for OS. Three SNPs (rs1385129, rs3820589 and rs3806401) were in linkage disequilibrium. In Cox proportional hazard models, GAA haplotype was a good prognostic factor for OS (hazard ratio [HR] = 0.57, 95% confidence interval [CI]: 0.39–0.81,  p  = 0.002) and PFS (HR = 0.68, 95% CI: 0.47–0.99,  p  = 0.043), compared to variant haplotypes. The GAA/GAA diplotype was observed in 46.7% of patients; these patients showed significantly better OS (HR = 0.38, 95% CI: 0.22–0.65,  p  < 0.001) and PFS (HR = 0.51, 95% CI: 0.31–0.85,  p  = 0.009) compared to those with other diplotypes.    Conclusions  These results suggest that polymorphisms of  GLUT1  gene could be used as a prognostic marker for patients with stage III NSCLC treated with radiotherapy.

Prognostic significance of genetic variants in GLUT1 in stage III non‐small cell lung cancer treated with radiotherapy